HR Execs on the Move

Onco360 Pharmacy

www.onco360.com

 
Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.onco360.com
  • 410, Park Avenue
    New York, NY USA 10022
  • Phone: 866.209.2178

Executives

Name Title Contact Details

Similar Companies

Legacy Pharmaceuticals International

Legacy Pharmaceuticals International is a Humacao, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Westminster Pharmaceuticals

Westminster Pharmaceuticals is dedicated to improving patient outcomes and reducing the cost of healthcare.

Albany Molecular Research

Albany Molecular Research is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Purdue Pharma

Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.